C’mon FDA, would you just get on with awarding priority review so the the company can finalise ph3 trial design ,and then announce to the market first patients dosed.
With a chemo free bettering of SOC and a lowering of toxicity and doubling of pembro when combined, this surely is a no brainer?
Media, page-612
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.5¢ |
Change
0.015(4.41%) |
Mkt cap ! $515.6M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 36.0¢ | 33.5¢ | $1.208M | 3.455M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 43 | 1259548 | 35.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.5¢ | 215354 | 33 |
View Market Depth
| Last trade - 13.52pm 18/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |